Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics of GH001 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05163691
Recruitment Status : Completed
First Posted : December 20, 2021
Last Update Posted : December 20, 2021
Sponsor:
Information provided by (Responsible Party):
GH Research Ireland Limited

Tracking Information
First Submitted Date  ICMJE November 18, 2021
First Posted Date  ICMJE December 20, 2021
Last Update Posted Date December 20, 2021
Actual Study Start Date  ICMJE June 21, 2021
Actual Primary Completion Date October 23, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 13, 2021)
The pharmacokinetic (PK) parameters derived from laboratory assay results of the systemic levels of 5-MeO-DMT and bufotenine [ Time Frame: up to 4 hours ]
For PK analyses, blood samples will be collected before and up to 4 hours after the administration of GH001 to determine 5-MeO-DMT and bufotenine serum concentrations.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: December 13, 2021)
  • Safety: Adverse Event (AE) reporting [ Time Frame: Up to 30 days ]
    Adverse events reported in the study and coded by MedDRA.
  • Safety: Frequency of clinically significant changes from baseline in electrocardiogram (ECG) recording [ Time Frame: Up to 7 days ]
    Clinically significant changes in ECG include any significant change in rate or rhythm as determined by the principal investigator
  • Safety: Frequency of clinically significant changes from baseline in vital signs measurement [ Time Frame: Up to 7 days ]
    Vital signs include heart rate (beats per minute), blood pressure (mmHg), respiratory rate (breaths per minute), oxygen saturation (%), and temperature (degrees celsius). Changes are defined as any clinically significant change from baseline as determined by the principal investigator
  • Safety: Frequency of clinically significant changes from baseline in safety laboratory tests of blood and urine [ Time Frame: Up to 7 days ]
    Safety laboratory analyses are analyses of blood samples (biochemistry, hematology) and urine samples (urinalysis). Changes are defined as any clinically significant change from baseline as determined by the principal investigator.
  • Safety: Frequency of clinically significant changes from baseline in Peak Flow Respirometry [ Time Frame: 1 hour after dosing ]
    Peak Flow is assessed using a standard peak flow respirometer, with the assessment done three times and the best of the three scores recorded as the final score (liters/minute).
  • Safety: Frequency of clinically significant changes from baseline in level of sedation [ Time Frame: 30 minutes and 1 hour after dosing ]
    The Modified Observer's Assessment of Alertness and Sedation scale (MOAA/S) will be completed before and after GH001 dosing. Scored from 0 (deep sedation) to 5 (alert)
  • Safety: Change from baseline in Clinician Administered Dissociative States Scale (CADSS) [ Time Frame: Up to 30 days ]
    Change from baseline in the Clinician Administered Dissociative States Scale (CADSS). The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76.
  • Safety: Assessment of Subject-Discharge readiness [ Time Frame: up to 3 hours after last study drug administration ]
    Assessment of Discharge Readiness on the administration day by the Principal Investigator, using the Clinical Global Assessment of Discharge Readiness (CGADR).
  • Mental Health: Change from baseline in Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Up to 30 days ]
    Change from baseline in the Brief Psychiatric Rating Scale (BPRS). A scale to measure psychiatric symptoms. Each symptom is rated 1-7 and a total of 18 symptoms are scored. Combined score ranges from 18 to 126.
  • Mental Health: Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Up to 30 days ]
    Change from baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS). A detailed questionnaire assessing both suicidal behaviour and suicidal ideation. No combined score is created.
  • Pharmacodynamic assessment: The dose-related psychoactive effects of GH001 as evaluated by a Visual Analogue Scale [ Time Frame: up to 1 hour after dosing ]
    The Peak Experience Scale (PES) is a Visual Analogue Scale scored from 0-100
  • Pharmacodynamic assessment: 30-Question Mystical Experience Questionnaire (MEQ30) [ Time Frame: up to 1 hour after dosing ]
    The MEQ30 is a validated procedure for assessing the extent of the psychoactive effects experienced by a subject. The validated MEQ30 uses thirty assessment questions across four areas of experience, all scored from 0 to 5.
  • Pharmacodynamic assessment: Challenging Experiences Questionnaire (CEQ) [ Time Frame: up to 1 hour after dosing ]
    Completed by the subject after GH001 administration and assesses seven factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) all scored from 0 to 5.
  • Pharmacodynamic assessment: Duration of the psychoactive effects (PsE) [ Time Frame: up to 1 hour after dosing ]
    The duration of the experience, defined as time in minutes from drug administration to time when the subject reports that any psychoactive symptoms have subsided will be recorded.
  • Cognitive Function: Change from baseline in Psychomotor Vigilance Task (PVT) [ Time Frame: Up to 7 days ]
    Change from baseline in the Psychomotor Vigilance Test (PVT). A computerized test assessing the reaction time in response to a visual stimulus. Outcome measures are Response Time and the number of attentional lapses (Response Time ≥ 500 msec).
  • Cognitive Function: Change from baseline in Auditory Verbal Learning Test (AVLT) [ Time Frame: Up to 7 days ]
    The AVLT is one of the most widely used word learning tests in clinical research and practice. The test is based on successive auditory presentations of 15-word lists followed by attempted recall. The AVLT outcome measures are the rate of learning as well as the level of recall.
  • Cognitive Function: Change from baseline in Spatial Working Memory (SWM) task [ Time Frame: Up to 7 days ]
    The SWM task requires retention and manipulation of visuo-spatial information. This self-ordered test provides a measure of strategy as well as working memory errors. The test involves a number of colored squares (boxes) shown on the screen which require a selection strategy to fill an empty column. The test takes about 4 minutes to complete. Outcome measures of the SWM include errors and strategy. The computerized Corsi Block will be the version of the SWM task used in this study.
  • Cognitive Function: Change from baseline in Digit Symbol Substitution Task (DSST) [ Time Frame: Up to 7 days ]
    Change from baseline in the Digit Symbol Substitution Test (DSST). A computerized test with the task is to match digits with symbols from encoding list. The number of digits correctly encoded within 3 minutes is the performance measure.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Pharmacokinetics of GH001 in Healthy Volunteers
Official Title  ICMJE A Phase 1 Study to Determine the Pharmacokinetics and Pharmacodynamics of Single and Multiple Inhaled Doses of GH001 in Healthy Volunteers
Brief Summary The primary objective of this study is to investigate the serum pharmacokinetics of 5-MeO-DMT and its metabolite, bufotenine in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, inhaled doses of GH001 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH001. As a secondary objective, the safety and tolerability of GH001, the mental health and well-being of the subjects after GH001 dosing(s), the pharmacodynamic profile of GH001 as evaluated by its psychoactive effects, and cognitive measures are also assessed.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This study will include separate single- and multiple-dose parts.

Single-dose Part:

A double-blind, placebo-controlled, randomized, parallel-group design with single, inhaled doses of GH001 in 3 groups of 10 subjects (randomized as 8 active and 2 placebo subjects per group):

  • Group A: single inhaled dose of 6 mg GH001
  • Group B: single inhaled dose of 12 mg GH001
  • Group C: single inhaled dose of 18 mg GH001

Multiple-Dose Part:

An open-label, non-randomized administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with two different dose intervals (8 subjects per group):

  • Group D: 1-hour interval
  • Group E: 2-hour interval
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Healthy Volunteers
Intervention  ICMJE
  • Drug: 5 Methoxy N,N Dimethyltryptamine
    GH001 administered via inhalation
    Other Names:
    • GH001
    • 5-MeO-DMT
  • Drug: Placebo
    GH001 Placebo administered via inhalation
    Other Name: GH001 Placebo
Study Arms  ICMJE
  • Experimental: Group A - 6 mg single-dose
    A single, inhaled dose of GH001 6 mg or placebo (randomized as 8 active and 2 placebo subjects)
    Interventions:
    • Drug: 5 Methoxy N,N Dimethyltryptamine
    • Drug: Placebo
  • Experimental: Group B - 12 mg single-dose
    A single, inhaled dose of GH001 12 mg or placebo (randomized as 8 active and 2 placebo subjects)
    Interventions:
    • Drug: 5 Methoxy N,N Dimethyltryptamine
    • Drug: Placebo
  • Experimental: Group C - 18 mg single-dose
    A single, inhaled dose of GH001 18 mg or placebo (randomized as 8 active and 2 placebo subjects)
    Interventions:
    • Drug: 5 Methoxy N,N Dimethyltryptamine
    • Drug: Placebo
  • Experimental: Group D - Individualized Dosing Regimen, 1-hour interval
    Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 1-hour dose interval (8 subjects)
    Intervention: Drug: 5 Methoxy N,N Dimethyltryptamine
  • Experimental: Group E - Individualized Dosing Regimen, 2-hour interval
    Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 2-hour dose interval (8 subjects)
    Intervention: Drug: 5 Methoxy N,N Dimethyltryptamine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 13, 2021)
46
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 22, 2021
Actual Primary Completion Date October 23, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject has a body mass index (BMI) in the range of 18.5 and 35.0 kg/m2 (inclusive);
  • Subject is in good physical health in the opinion of the principal investigator (PI);
  • Subject is in good mental health in the opinion of the PI and clinical psychologist;

Exclusion Criteria:

  • Has known allergies or hypersensitivity or any other contraindication to 5-MeO-DMT;
  • Has received any investigational medication within the last 4 weeks;
  • Has a medical condition, which renders the subject unsuitable for the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 64 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Netherlands
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05163691
Other Study ID Numbers  ICMJE GH001-HV-103
2021-000241-40 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party GH Research Ireland Limited
Study Sponsor  ICMJE GH Research Ireland Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: GH Research Clinical Team GH Research Ireland Limited
PRS Account GH Research Ireland Limited
Verification Date December 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP